Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10877986 | 0.84 | ALDH1A1 (0.46) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL16570667 | 0.83 | ALDH1A1 (0.43) | ALDH1A1RAB9AATML3MBTL1TRPM8 | |
| SCHEMBL6512103 | 0.82 | ALDH1A1 (0.53) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL8063671 | 0.82 | ALDH1A1 (0.53) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL11067886 | 0.80 | ALDH1A1 (0.50) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL1836770 | 0.78 | ALDH1A1 (0.49) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL28335652 | 0.78 | ALDH1A1 (0.57) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL14984401 | 0.78 | ALDH1A1 (0.47) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL9164717 | 0.76 | ALDH1A1 (0.47) | ALDH1A1RAB9AATMTDP1L3MBTL1 | |
| SCHEMBL6516470 | 0.75 | ALDH1A1 (0.56) | ALDH1A1RAB9AATMTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | APPLIED NANOSYSTEMS B.V. (NL) | 2005-12-08 | — | — | US | disclosed |
| EP-1490028-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | Applied NanoSystems B.V. (NL) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084508-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | APPLIED NANOSYSTEMS B.V. (NL) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | TACR1, TACR2, NPSR1 | ALDH1A1 788/4885RAB9A 3682/4885ATM 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.